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ardial failure results in i~ad~~~~t~ s fl~i~ 
ion of intracardiac pressures and activati~~n Q 
satnry neurohormonal s (I-6). It is well 
an~~otensin co verting e inhibitors, which counteract 
the effects ofthe renin-angiotensin and, to a lesser degree, the 
hetic nervous system (5), are beneficial in myocardial 
(2,7,8). Since 1975, when ~a;~~stein t al. (9) first 
reported ‘,e beneficial effects of beta-adrenergic blocking 
agents OR heart failure, several investigators (1,104) have 
et&atb 
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01994 by the American College of Car&logy 
f~use~ on the use of these agents to antagonize the e 
~~~ro~i~ 
from ou 
improved ejection fraction and fun 
with dilated ~ardiamyopat~y treated with beta-blockers, these 
agents remain an enigma. It is co~at~rint~itive that a ‘“negative 
inotrope” would result in improved ventricular performance in 
patients with myocardial failure. Because our previous trial 
(10) was an open label study of bucindolol, a nonselective 
beta-antagonist with weak vasodilatory properties (19), it 
remains unclear whether such salutary hemodynamic effects 
would extend to a beta-blocker without direst vasodilatory 
~ro~rties and without direct va~odilato~ 
without beta-antagonism. ‘I’berefore, we sought to determine 
whether metoprolol, a pure beta,-antagonist, improves myo- 
cardial performance and eticiency in patients with dilated 
cardionqnpathy. 
Finally, the metabolic effects of beta-blockers in patients 
with heart failure havs not been elucidated. It is well known 
that fatty acid oxidation by the heart uses more oxygen per unit 
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Meaq9rolol Placebo P 
GrQUp (n = 15) Group (n = 9) Value 
s 
er 1, %990 and April 14, 1993, 25 
age 48 f 10 years, range 34, to 75) 
nonischemic dilated cardiom thy underwent cardiac cath- 
eterization at the Dallas V ans Ad~~i~istrat~o~ -Medical 
ventricular ejection fraction 
were in New York eart 
to IV. All patients with a 
cardiomyopathy were ap- 
into the study unless they had a complicat- 
with severe renal (creatinine >2.5 
amic oxaloacetic ransa 
[SGPTj more than three 
times normal), pufmonary,  ogic or endocrine disease 
were exchrded. Only one patient was diabetic and was taking 
ization, and he was a well 
ats with previous myocardial 
or bypertrophic cardiomy- 
opathy or ~rirna~ valvular disease were excluded, as were 
patients with a recent (~3 months) history of alcohol abuse. 
Five (56%) of 9 controi patients and 8 (53%) of 15 metoprolol- 
some history of akobd abuse (Table i) 
bo vs. rn~to~~o~o~~. In addition, two of niue 
ients had stopped rinking <6 months (but 
>3 months) before ntry into the study, whereas none of the 
metopsolol-treated patients had a history of drinking ~6 
months before ntry (p = NS). All patients with <6 months of 
clinical heart failure of unclear etiology had endomyocardial 
biopsy; none had evidence ofmyocarditis. 
ABI medications were allowed, e 
3 months of eatry Ah patients 
converting euzyme inhibitors duri 
nous dextrose was given before c erization. Written in- 
formed consent was obtain 
the Human Studies Sub 
i~~strat~o~ and Uuiver 
e to record 
Baseline coronary sinus tkemodilution and cardiac output 
measurements a d left heart pressure cordings were performed 
before initiation ofoverdrive atrial (ccmnary sinus) pacitrg. 
at& hearr rate at baseline and 3 months) 
ed to eliminate ait~ati~~s in ~o~t~a~ti~i~ and 
relaxation due to changes in heart rate from baseline t0 3 
months. Ten minutes after initiation ofatrial pacing at 10 to 15 
beats/mitt above the intriusic heart rate, lef? heart pressure and 
cardiac output measurements were repeated. This was fool- 
Iawed by digital ventriculograp y using 15 to 25 ml (total 
(60:40) nouionic ontrast media (fohexol, 
aboratories). Ventricu!ography was per- 
formed in the 3V’ right amerior oblique projection at 30 
frames/s with cineradiographic equipment (Philips nr04el Op- 
timus w1200, Eindhoven, The Netherlands) interfaced directly 
to a digital radiographic computer ( 
41OOC, Milpitas) arrd stored as a 512 
matrix. The images were stored and processed using previously 
published techniques (I ). 
rements were recorded, loading condi- 
a~~ta~ni~i~. Intravenous 
sodium nitroprusside was initiated at a ose of 0.25 to 0.50 
&kg body weight per min and increased by0.25 @,kg per mm 
every 2to 5 min to achieve a reduction of15 ts 29 mm Hg in 
aortic end-systolic pressure. Care was used to avoid bypoten- 
sion. Repeat simultaneous ventriculograms and hemody 
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namic recordings were performed at one or two time points 
after aortic end-systolic pressure had been altered. Because 
feft ventricufography ma  increase end-diastolic pressure tran- 
sientfy, there was a delay of at least 10 min between ventricu- 
fograms toallow the left ventricle to return to equilibrium. 
After 3 months of therapy, the same procedure was used 
with care to match the original atrially paced heart rate used in 
the baseline study. 
All patients underwent selective coronary arteriography at 
the end of the 50 catheterization t  exclude significant 
co disease as a cause of their cardiomyopathy. 
~t~~Q~. The study drug (metoprofot or placebo in B 
3:2 randomization) was 
twice daily. All patients 
prolol tolerated titration to f’ulf dosage. 
Plecebo-treated patients crossed over to open-label meto- 
onth study period. We performed a radio- 
am 6 m~~tbs after randomization (i.e., 
n-label metoprofof) to assess the change 
in left ventricular ejection feaction after crossover toactive 
drug* we had no knowledge of who received the active 
drug i tia13 months, the drug was titrated or retitrated 
in all patients according tothe schedule given earlier. Because 
clinical deterioration has been noted in patients witb~rawn 
from beta-blockers (12,25), we chose not to cross the active 
patients over to placebo. In addition, this allowed us to 
determine whether further changes inleft ventricular ejection 
d htween 3 and 6 months. 
sis, Left ventricuf~r voluma was 
standard angiqrapbic area 
cardiac yle sefeckd was not a premature beat or post- 
hat. Simultaneous left ven 
nt in the cardiac cycle. ~ntraob~~er and 
of our digital ventricnfogr~m measure- 
To test whetfter ftexformance 
placebo groups, we prospectively 
well as tfuee relativefy load- 
elastataoc, derived from the end 
relation (lOZU9); 2) peak positive lirst detitive of left ventric- 
ufar mure (+dRdt) to end-diastolic volume relation (30); and 
trike work (31). ‘Ike indexes were 
d heart rates before and after 3 months 
index (LVSWI) was 
LVSw = (MSLVP - MDP) X SVI x 0.01J6, 
where MSLVP = mean systolic left ventricular pressure; 
I+JDp = mean diastolic left ventricular p essure; and SVI = 
stroke volume index by thermodifution (cardiac jndexfleart 
rate). f%ute work index = LVSWI x Heart rate. 
Arterial elastance (Ea) was determined by a previously 
validated formula (33,34): = PeslSV, where Pes = end- 
systolic pressure; and SV = 
Assessment oj ~~#~t~li~ ~e~~~~~ce” 
Left ventricular relaxation was assessed byanalyzing changes 
in the time constant of e.~oncntial isovol~metric pressure 
decrease (au) uncorrected forafterload (35,36) and the slope 
of the tau-end-systolic pressure r lation 
and after long-term beta-~dr~ner~ic bloc 
The time constant of 
ed by a previously described 
~~a~lber stiffness was 
opening to the peak of the 
(ECG). A no~lin~r eq~at~o~~~tti 
Products) was used to solve the eq 
coelficients a, b and k were 
equation; coefficient k 
coefficient a = the upward or downward dispf 
of the @ress~~~-vofMn~c relation. On the basis o
a slope I&, where KN = a measure oImyocardiaf stiffness (39). 
Detemaimation of myocmdid eficiemy. Myocardial oxygen 
consumption (MQC) was determined bythe following formula 
(10): 
X (Left ventricular - Coronary sinlas 02 difference); 
and myocardial efficiency fl  (lo), 
Efficiency (%) = (Stroke work X Heart rate/k X MOC), 
where k = conversion constant 2.059 (kg-m/ml 0, consumed). 
Because our determination f mechanical efficiency is caf- 
cufated by this ratio of external mechanical work to myocardial 
oxygen consumption (as just shown), and because total me- 
chanical energy actually represents both external mechanical 
work and potential ene changes, we also calculated poten- 
tial energy changes before and after therapy. We calculated 
potential energy by a calculation based on end-systolic pses- 
sure (V,), and end-systolic volume (ESV) using the following 
formula (40): 
Potential energy ={[(End-systolic pressure) x (ESV - &)jL?} 
X (1.33 X lob4 J/mm Hg-ml). 
ed between eat~~ter- 
- ko2j/(A02 - Cso2j, 
ible arn~u~t of carbon dioxi 
tent was calculated as
02 content (mlldl) = (02 sat %o) (1.46 ml 82/g Hgb) (Hgb g//dl); 
Q content OnmolAiter) 
= {[02 content (ml/dl)](lO dl/liter)j/(22.4 ml/mmol), 
where sat = saturation. Variability ofour 
tory quotient measurements has been tested by repeated 
analysis ofmeasurements from seven paLent 
cardial respiratory quotient taken 30 s apart (1 
patients crossed over by &ration to open-label metopro~o~. All 
patients were then asked to undergo aradionuclide v ntricu- 
logram at 6 months after andomization. O e patient did not 
receive a &month scan because of sudden death before the 
scan; another patient from the placebo group was intolerant to
metoprolol titration because ofsevere heart failure and did not 
undergo a 6-month scan. Radionuclide v ntriculography was
performed and analyzed as previously described (43,44). All 
radionuclide studies were analyzed inblinded manner. 
Statistical analysis. Changes in hemodynamic variables 
and ventricular function were compared by two-way (group 
effect and time effect) repeated measures analysis ofvariance. 
rences between groups were then tested by a 
Scheffi F test. Differences within groups were tested by a 
Student paired t test only if the repeated measures analysis 
demonstrated an intrngroup time effect. Baseline characteris- 
tics were compared by an unpaired t test. For the peak 
+dPidt-end-diastolic volume relation, a repeated measures 
analysis ofcovariance (with end-diastolic volume as the covari- 
ate) was use3 with 1) intergroup (metoprolol vs. placebo) and 
kra8roup (time effect adl 
examined. F0r end-s~skol~c ePa 
of each i~d~v~~ua~ patient 
eated ~e~$~res an 
ho-way repeated meas 
Cke~~st~c~~ One of the 25 original ~atiessts 
cardiac athetc~~~at~o~l and was cxc~ude~ 
nstrated inTable 1, bot 
relaxation. 
fteen patients were randomized to re- 
9 to receive placebo. All patients oler- 
g twice daily without 
nts during titration, ar! 
1 admission for worseni 
the two groups are summarized in Table 2. Heart rate was 
uced by meto~rolo~, thus accounting for a lack of incr 
ardiac output despite an increase in stroke volume. 
ventricular end-diastolic pressure at rest was not r 
metoprolol. wevea peak systolic and end-systoli 
were increa by beta-blockade. 
0th stroke and minute work were increased by metoprolol, 
ereas potential energy did not change (Tables 2 and 3). 
espite this increase in mechanical work, coronary flow and 
myocardial oxygen consumption decreased. This resulted in an 
increase in myocardial efficiency in the metoprolol group only 
(from 8.5 2 5.6% to 18.5 4 10.9%, p = 0.01 vs. pretherapy, p = 
0.10 vs. placebo), 
Despite improvement inventricular performance and myo- 
cardial efficiency, coronary sinus uorepi~ephrine did not de- 
crease. However, compared with the placebo group, 
prolol attenuated progressive increases in coronary sinus 
nephrine and epinephrine. 
toiis ~ss~ss~~~~, At matched paced heart rates, meto- 
increased end-systolic and reduced left ventricular en 
diastolic pressures (Table 3). Despite these changes, end- 
systolic volume decreased, and ejection fraction increased, in 
the metoprolol group (Table 3, Fig. 1). Stroke work increased 
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Table 2.. Baselim Left Ventricular Characteristics Before and After Metoprolol or Placebo 
Before After p Value 
Treatment Treatment (metoprolol vs. placebo) 
Heart rate (mitt-‘) 
Placebo 
Metoprolol 
Cardiac output (liters/min) 
Placebo 
Metoprolol 
Stroke volume (ml) 
Phi&o 
Metoprolol 
L 
systolic pressure (mm Hg) 
Metoprolol 
End-soytolic pressure (mm Hk) 
Placebo 
Metoprolol 
Stroke work index (g-m/mz) 
PlaCebo 
Metoprolol 
Minute work index (kg-m/m’) 
Placebo 
Metopmlol 
Coronary sinus blood flow (ml/mitt) 
Placeho 
Metoprolol 
Myocardial oxygen difference (vol %I) 
PI W&O 
Metoprolol 
Myocardisl ox-ytyt consumption (ml/min) 
Plaaho 
Comnaty sinus tmwpinephrine 
PlXt?bo 
ol 
nus epinepttrine (pgiml) 
Plaeeho 
Metopmlol 
Respiratory quotient 
Placebo 
Metopmlol 
4.2 2 1.4 4.4 ?I 1.2 
4.12 1.2 4.8 z i.c 
52 2 20 
59 ‘c 19 
56 + 22 
74 ?I 2.W 
28.6 2 5.7 26.8 f 7.8 
19.1 t 9.4$ 16.8 L 7.3 
WJ*8 IO2 + 6 
105 t 21 124 + 2Qt 
61 26 6027 
62 2 14 77 * 19t 
17.0 s+ 5.0 20.3 2 IO.9 
18.7 ?z 7.8 32.9 t 17.5’ 
1.4 r 0.4 
1.5 t 0.6 
1.6 2 0.7 
2.1 ?I 0.W 
146 ? 102 201 2 136 
178 r 88 115 + 71 
12.2 r 1.7 11.5 t 2.3 
12.4 + 1.3 11.7 c 1.2t 
16.8 r 9.2 22.1 ?C 12.5 
22.3 + 11.3 13.1 t 1.6 
1.9 + 3.8 9.2 c 6.1 
85 c 5.6 18.5 2 10.Qt 
730244% 1.114 9 727 
569 C% 426 433 t 357 
866f8a 
65 + 55 
135 lr 174 
46236 
0.88 I 0.25 
0.70 2 0.27 
0.68 t 0.15 
0.78 2 0.25 
0.014 
0.76 
0.19 
U.91 
0.017 
0.023 
0.25 
0.026 
0.95 
0.035 
0.10 
0.025 
0.09 
0.054 
‘p < 0.003 versus before treatment. $p < 0.05 versus before treatment. $ p c 0.05 versus before treatment with 
plaabo. Data presented are mean value + SD. LVEDP = left ventricular end-diastolic pressure. 
only in the metoprolol group despite the finding that preload, 
reflected by end-diastolic volume, decreased. 
Lcft ventricular ejection fraction increased in 13 of 15 
patients randomized to metoprolol treatment by3 months of 
therapy. One of the remaining two patients had an improve- 
ment in ejection fraction by 6 months compared with baseline, 
Thus, 14 (93%) of 15 patients had some improvement i  
ejection fraction by 6 months. By 3 months of metoprolol 
therapy, 10 (67%) of 15 patients experienced anincrease of
0.05 in ejection fr~&_u~, e (4u%) olt 15 had an increase of0.10; 
and 3 (20%) of 15 had an increase of 0.20. By 6 months of 
metoprolol therapy, 11 (79%) of 14 patients assessed xperi- 
enced an increase of 0.05 in ejection fraction; 10 (71%) of 14 had 
an increase ofO.lQ and 6 (43%) of 14 had an increase of0.20. 
Although end-systolic elastance did not increase in the 
placebo and metoprolol groups, the y intercept of the 
end-systolic pressure-volume r lation was increased in 
the metoprolol group (Table 3). This suggests that a parallel 
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%b8e 3. Left Ventriczmlar Characteristics During Atrial Pacing Before and After Study Drug Therapy 
Measuremenr 
Before 
Treatmenr 
After 
Treatment 
p Value 
(mctoprolol vs. placeho) 
Heari Raw and Prcssurcs 
Wcart raw (rniil ‘i 
Placebo 
Metoprobl 
LVEDP (mm Hg) 
Placeho 
Meroprolol 
End-systolic pressure (mm Hg) 
Placebo 
Metopr&i 
Aortic end-diastolic pressure (mm Hg) 
PlWL4X~ 
Mcroprolot 
Potential energy (.I) 
PlitCCllU 
Meq~rolol 
EDVt (ml/m:) 
Placcho 
Mewprolol 
ESV! (mum') 
Plxrbo 
Mctoprolol 
LVEF 
Placebo 
Metoprolol 
Ees (mm &/ml) 
Placeho 
Metoprolol 
Ees y inlcrcepr (mm Hg) 
Placebo 
Metoproiol 
Ea (mm H&‘/ml) 
Placebo 
Metoprolol 
Stroke work index (g-m/m’) 
Placebo 
Mctoprolol 
Peak +dP/dl (mm l-I@) 
Placebo 
Metuprolol 
PRSW (g-m/ml) 
Placebo 
Metoprolol 
95 I5 8 97 f 9 
942 13 935 13 
26’+ .- - 59 . . 25.8 c 9.5 
19.2 5 lU.6* 12.5 rr 7.4; 
(12 ? 4 59 2 9 
62 +_ 13 72 +. 17t 
70 It 5 77 2 l-l 
79z IS 78-t 14 
1.40 _k I.08 1.25 z Oh8 
1.17 2 1.t.l I.26 2 1.26 
Volumes and Syswlic Propertics 
_I_- I__l_-j.p 
177 2 Sh 159 * 63 
137 z 36$ lilb i 37t 
I.54 t 5.t 134 tl so 
IOX 2 36:k 80 2 37$ 
0.14 2 0.07 0.17 + 0.08 
0.22 + O.lO$ 0.33 2 0.13$ 
0.63 2 0.48 0.53 +- 0.19 
0.81 2 0.4x 0.84 -t 0.39 
-82 2 154 -48 rT 52 
-84 2 llh -11 _f 34t 
2.9 r. 2.2 2.6 f 1.7 
1.X 2 0.8 1.7 z 0.8 
16.4 -c 5.4 17.1 2 6.2 
I0.Y -c 7.11 27.0 z 1S.l-l 
774 5 101 WY z 5s 
x75 z 2.x 1.073 2 3sg 
0.12 f O.OH 0.U6 2 0.04 
0.18 + 0.16 0.35 + 0.24t 
0.11 
0.15 
O.&i3 
0.85 
0.57 
IL84 
0.44 
u.05 
0.66 
0.49 
U.83 
0.1  
0.04 
0.08 
Diastolic Properties 
Peak -dP/dt (mm Hg/s) 
Placebo 
Meloprolol 
Tau (ms) 
Plncebo 
Mctoprolol 
R (mslmm ftg) 
Placebo 
Metoprolol 
787 2 76 808 -c 104 
922 + 2.54’ 1,106 2 3311 0.097 
123 of: 25 104 + 32/I 
x9 + 258 7R 2 2411 0.41 
3.5 ? 1.7 2,s -c I.511 
1.5 -c 1.0s 0.8 -t 0.81 OSH 
KN 
Placebo 
Metoproiol 
9.8 f 5.0 1 I .o z! 8.0 
3.7 2 3.0$ 3.4 _+ 2.6 (X7 
k 
Placebo 0.031 ? 0.021 0.042 2 0.036 
Metoprolol 0.031 + 0.035 0.031 +_ 0.040 0.64 
a 
Placebo 4.46 + 15.80 -1.38 + 17.57 
Metoprolol -5.16 2 25.11 0.13 = 10.68 0.37 
‘p < 0.1, #p < 0.05 versus placebo pretreatment, ‘rp < 0.05, §p < 0.01, lip < 0.1 versus pretreatment. Data presented arc mean value ?r SD. a = diastolic 
pressure-volume shift coefficient; Ea = arterial elastance; Ees = end-systolic elastance; EDVI (ESVI) = end-diastotc (end-systolic) volume index; k = constant of 
chamber stiffness; KN = myocardial stiffness; LVEDP = left ventricular end-diastolic pressure; LVEF = left ventricular ejection fraction; Peak +dP/dt (-dP/dt) = peak 
positive (negative) fust derivative of left ventricular pressure; PRSW = preload recruitable stroke work; R = end-systolic pressure relation; Tau = time Constant of 
exponential isovolumetric pressure decrease. 
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ra are pup mean value and error. 
ard shift) occurred in the ~~~-§~t~lic 
ressure-volume relation consistent with either an increase in
or a reduction i ventricular volume, or 
Peak +dP/dt at matched paced heart rates increased with 
bta-blockade (p = 0.023), an effect that is not explained by an 
increase in preload (Pig. 2). The slow of the stroke work-end 
diastolic volume relation demonstrated an increase inpreload 
recruitable stroke work in th oprolo! group only (Table 3). 
Taken together, these data st that lon~~~rrn mcto~ro!~~! 
therapy may increase contractility in patients with dilated 
ic n~~s$mg~t. Although isovolumic re!~~tion im- 
ith metoprolo! (as rc~~ctcd bya decrease in 
of ~x~n~nti~l i vo!umetri~ decrease taff, 
the ta~~n~~tolic pressure r lation [R] and an increase in
c&o group likew!se had a small 
us, the metoprolol group did not 
lacebo group. The reduction i
entia! isovolumetric decrease (tau) 
p&ably would have been more 
prominent had end-systolic pressure not increased in this 
(3637). 
ddiastolic volume and pressure decreased in the meto- 
group (Table 3). However, myocardia! stiffness and 
chamber sti!Tness did not change with therapy. Inaddition, the 
diastolic pressure-volume relation was not shifted upward or 
downward with administration f metoprolo! r placebo, as 
lack of change in coeWcient “a.” Thus, metoprolol 
ificantly improve diastolic function ~rn~red with 
tics and neu~ho~Q~~1 tiv~tio~. 
umption decreased despite increase 
in !eftventricu!ar minute work (Table 2), suggesting improved 
myocardia! efficiency with beta-blockade. 
Myocardia! respiratory quotient tended to increase inthe 
metoprolol-treated patients, whereas it tended to decrease in
the placebo-treated patients (Table 2). These data suggest that 
beta-blockade alters ubstrate utilization by incr~sing carbo- 
hydrate utilization (increased myocardia! respiratory quo- 
tient). By comparison, placebo-treated patients had a progres- 
sive increase in noncarbohydrate u ilization (reduction in 
respiratory quotient). Although the intragroup changes in 
respiratory quotient did not reach statistical significance (p = 
0.36 for the metoprolo! group vs. pretherapy and p = 0.12 for 
group vs. pretherapy), the intergrou 
at metoprolo! at least may inhibi 
he respiratory quotient (p = 0.054). 
Changes in coronary sinus norepinephrine closely core- 
lated with changes inmy~~dia! res~irato~ ~~Qtie~t (Pig. 3). 
These data suggest that a relation may exist between euro- 
hormonal ctivation and substrate utilization i patients with 
heart failure. Despite this correlation, o relation was seen 
h ~~~~~~~~~~~~~~~~§ and 
m, the left ventricular 
-f 0.80 at bassline to 
0.32 * 0.13 at 3 months (p = 0.0013 vs, baseline) to 0.41 + 0.13 
at 6 months Qp = 0.017, 6 months vs. 3 months). En the seven 
ients who had all three assessments, ejection 
0.13 2 0.0s lo 0.17 t 0.09 at 3 manths (p = 
nd increased to 0.28 + 0.09 3 months after 
crossover to metoprolol (p = 0.011 vs. 3 month 
class improved over the 6 months of fdlow- 
metoprolol-treated patients. Functional class w 
baseline, 2.1 1- 0.7 at 3 months = NH vs. baseline) and 
impaQved to 1.5 2 0.7 by b mm of therapy (p < 0.05 vs. 
baseline and vs. 3 months). Functional class did not change in 
the placebo-treated group over the 3 months of double-blind 
therapy. 
The use of beta-adrenergic blockade to treat patients with 
heart failure remains an enigma, Improvements in ventricular 
function in the presence of a “negative” inotropic agent is 
counterintuitive and remains controversial despite aconsider- 
able number of published reports (1,9-18) that demonstrate a 
salutary effect of these agents in these patients. Our study 
demonstrates improved left ventricular function and a reduc- 
tion in left ventricular chamber size in patients with dilated 
cardiomyopathy randomized to metoproiol therapy. Additian- 
ent in three relatively k~ad independent indexes 
of performance, the end-systolic pressure-volume r lation, 
peak +dP/dt-end-diastolic volume relation and slope of the 
stroke work-end-diastolic volume relation suggests hat left 
ventricular contractility may have increased, although the 
long-term changes in heart size precludes our ability to state 
this definitively. 
as expressed by left 
seen in the placebo-treated patients. Such a reduction in 
~d-d~asto~~c pressure may represent one beneficial effect of 
eta-b~~c~~~~ ager~t~ OII these patients when they exercise 
16,i ‘9,46). As heart rate increases, beta-blockers 
increase in end-di ic pressure with exerAse. As with OUP 
cindolo! (IO), there was an intragroup 
(reduction in the tau-end-systolic 
no intergroup eikct was seen be- 
i~~~Q~~~~~t in the placebo group 
ic pressure in the mctopmlol gmp, 
ement in relaxation times (36 
I-k improveverncnt, metoprol id not 
significan$J reduce COrOfla sinus nrorepincphrine. This may 
have been due to the fact B metopmlol reduces the cl 
. By contrast, metoprolol 
retard the progressive increase in B1pore nephrine seen in the 
1acebo group (p = O.K.?5 vs. placebo) nd alsO reduced rest 
cart rate (p = 0.014 vs. placebo), a marker of receptor 
blockade and adrcnergic antagonism. 
Although myocardial respiratory quotient did not signifi- 
cantly increase with beta-blockade, metoprolol blunted the 
progressive decrease in respiratory quotient seen in the pla- 
cebo group (p = 0.054 vs. placebo). Thus, metoprolol may have 
resulted in preferential carbohydrate utilization. We believe 
that this is the first study to suggest an in vivo relation between 
substrate utilization and adrenergic activation in pat&s with 
heart failure. This finding is not surprising in view of previous 
animal studies demonstrating increased lipoiysis (21,24) and 
reduced insulin-induced glucose transport (48) in the presence 
of catecholamines. In addition, previous data in patients with 
heart failure have shown e ted insulin-mediated suppres- 
sion of hepatic glucose out increased glucose and lactate 
uptake and a decline in basa fatty acids with the long-term 
administration f metoproloS(49,§0). Because congestive h art 
failure is a state of increas drenergic stimulation, with 
elevated sympathetic nerve tr and increased plasma nor- 
epinephrine l vels (2-6), lipolysis and glycogenolysis may be 
stimulated (21,241. Beta-blockers may act to reduce effective 
postsynaptic norepinephrine and shift the balance of substrate 
selection in favor of carbohydrate. 
Several experimental observations suggest that hatv acid 
metabolism by the heart is less efficient han carbohydrate 
metabolism, a factor which may be hemodynamically relevant 
in the setting of catecholamine excess and limited oxygen 
delivery (20,24). Although fatty acid utikZ3tiOla in th@ prf2Xnck: 
Of this stress may serve to decrease myocardial efficiency, the 
lack of a direct relation between changes in respiratory quO- 
tient and changes in efficiency in this study suggest that this is 
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either not a factor or not the only factor esulting inimproved 
efficiency. Further investigation i to the mechanism(s) 
irirr;r&y beta-blockade improves myocardial efficiency is wai- 
ranted using more sophisticated methods, uck as magnetic 
resonance spectroscopy, roton emission tomography and 
molecular techniques. 
tions, The main limitation of this study was 
randomization t  achieve identical patients in
the metoprolol and placebo groups. Despite this limitation, the 
metoprolol group clearly responded more favorably totherapy 
both clinically and in terms of left ventricular systolic function. 
Even the more impaired placebo group was capable of re- 
sponding to therapy, as manifested by improved ejection 
fraction after crossover toopen-label metoprolol. Inaddition 
line differences, there was some s~n~~neons improve- 
ment in ejectian fraction in four of the nine placebo-tre~~ted 
patients, which reduces the statistical si~nifi~~~n~~ of our find- 
, However, spontaneaus iniprove~~~n& in ejection fraction 
in a substantial pa tion of placebo-treated patients with 
dilated cardiomyop is not unique to our trial and has been 
seen in other large randomized trials (17,lS). That we reached 
cance despite these baseline differences and 
ous improvement i  he placebo group attests 
to the very consistent improvement seen with metoprolol. 
Another limitation of this study is our limited ability to 
measure myocardial metabolism in vivo. Myocardial respira- 
tory quotient has a relatively large standard error and may be 
insensitive to small changes insubstrate utilization. We thus 
believe that our results are suggestive but require further 
investigation. 
Nitroprusside may result in geometric alterations a  ven- 
tricular volumes decrease, and could introduce an error into 
the volume calculations. In addition, in certain circumstances 
of large volumes constrained bythe ~r~~ardium, application 
of nit ‘de (or drugs that reduce ventricular volumes over 
time) ult in a downward shift of the diastolic pressure- 
vh.me rehtion as the constraint is relieved (51). l!n circum- 
where there was a clear downward shift of a pressure- 
loop with nitroprusside, the pressure-volume diastolic 
points before that application of nitroprusside were used. 
itroprusside may also result in some baroreflex- 
nges in contractility (52). However, because 
tients with congestive h art failure have high neurosympa- 
tic tone at baseline (2,4-6,X!), baroreflex stimulation from 
nitroprwide should be of minimal significance. In addition, 
the Small range of pressure reduction (15 to 25 mm Hg) 
induced by nitroprusside may hap: Z:,ted the accuracy of
the end-systolic pressure volume relation, especially 
at curvilinear (53,512). 
The comparison f left ejection fraction at 6 and 
3 months involves use of two diierent techniques: angiographic 
I& ve 
former 
and radionuclide v ntriculography. T e 
tric assumptions to assess ejection fraction 
(26Xk the latter makes no geometric assumptions (43,44). 
mite these differences, these two techniques have been shown 
to correlate well with each other (44). In addition, comparison f 
36 studies of patients with dilated cardiomyopathy by radionu- 
elide and angiographic lteclmiqnes in our in~tit~~ti~~ have shown 
excellent correk&r! (r = 0.78, SEE 
previous studies (55) have demons 
tion fraction with atrial pacing, because the ejection fraction at 3 
months was determined with atrial pacing and that at 6 aortas 
was determined at rest, some slight overestimation of ejection 
fraction at 3 months may have occurred. ever, this makes the 
improvement seen from 3 to 6 mouths much more signifi- 
cant. 
Measurement of left ven ar performance in vivo 
a lo~8”t~~ln i te~~~~t~~~~ is 
of left ventricular function is iW 
ventricular p~rrorn~at~~~ t  
intrinsic ~~yo~a~d~a~ fun& 
that c~~~~n~~~er p~rformi~n~~ 
parallel eftward shift in 
IThtiOfl, 2) iill increase in I 
the setting of reduce 
pressure, 3)an upward s 
volume relation, and 4) an incre 
stroke work. Although long-term changes inventricular size 
and 8eorn~t~ could expla’ our data, it is like6y that such 
changes in the ventricle ect improvement i  contractile 
performi~nce. indeed, ~ed~~~tio~ in ricuiar volumes by itself 
suggests that cardiac function has 
Because previous studies (57) e shown that the peak 
~d~~dt-end-diastolic volume relation is more sensitive than 
the end-systolic pressure-volume r lation for detecting 
~~~~~~8~s in ~ ~tro~i~ state, it is not im~o~sisteflt o have a 
parallel shift in elastance with an increase inthe 
d&-end-diastolic volume relation. In addition, the upward shift 
in the peak ~d~/dt-end-diastolic v ume relation in this case 
cannot be due to a change in aortic pressure because aortic 
end-diastolic pressure (aortic valve opening pressure) was 
unchanged after ~~dnlinistration of meto~roto~. 
We recognize that coronary sinus thermodilution determi- 
nation of coronary sinus blood flow is limited by changes in
catheter position within the coronary sinus, patterns incoro- 
nary venous drainage and coronary sinus refux (58,59). We 
attempted tominimize these problems by meticulous exami- 
nation of catheter position during each procedure. In addition, 
the presence ofa placebo-treated group in this study helps to 
assess the significance of any random measurement rrors. 
Finally, it is clear that he analysis ofmyocardial energetics 
is complex. Myocardial efficiency an be defined as the relation 
between myocardial o.xygen consumption a d its covariate, the 
pressure-volume ar a (total mechanical energy) (40). Total 
mechanical energy may further be defined as the sum of 
external mechanical work plus potential energy produced 
during a cardiac ycle. Because xternal mechanical work 
(stroke work) increased, potential energy was unchanged, and 
myocardiai oxygen consumption decreased, it is likely that 
myocardial efficiency increased. This increase is most likely due 
to an increase inshortening work as opposed to pressure work 
because potential energy did not increase substantially and 
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ment seen the 
ears to nmme left ventris- 
erits further investigation 
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